Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
AIM: Familial hypercholesterolemia (FH) patients are at high risk for premature coronary heart disease (CHD). Despite the use of statins, most patients do not achieve an optimal LDL-cholesterol goal. The aims of this study are to describe baseline characteristics and to evaluate Lipid Lowering Therapy (LLT) in FH patients recruited in SAFEHEART. METHODS AND RESULTS: A cross-sectional analysis of cases recruited in the Spanish FH cohort at inclusion was performed. Demographic, lifestyle, medical and therapeutic data were collected by specific surveys. Blood samples for lipid profile and DNA were obtained. Genetic test for FH was performed through DNA-microarray. Data from 1852 subjects (47.5% males) over 19 years old were analyzed: 1262 (68.1%, mean age 45.6 years) had genetic diagnosis of FH and 590 (31.9%, mean age 41.3 years) were non-FH. Cardiovascular disease was present in 14% of FH and in 3.2% of non-FH subjects (P < 0.001), and was significantly higher in patients carrying a null mutation compared with those carrying a defective mutation (14.87% vs. 10.6%, respectively, P < 0.05). Prevalence of current smokers was 28.4% in FH subjects. Most FH cases were receiving LLT (84%). Although 51.5% were receiving treatment expected to reduce LDL-c levels at least 50%, only 13.6% were on maximum statin dose combined with ezetimibe. Mean LDL-c level in treated FH cases was 186.5 mg/dl (SD: 65.6) and only 3.4% of patients reached and LDL-c under 100 mg/dl. The best predictor for LDL-c goal attainment was the use of combined therapy with statin and ezetimibe. CONCLUSION: Although most of this high risk population is receiving LLT, prevalence of cardiovascular disease and LDL-c levels are still high and far from the optimum LDL-c therapeutic goal. However, LDL-c levels could be reduced by using more intensive LLT such as combined therapy with maximum statin dose and ezetimibe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Civeira, F. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.11.010 · Cited by 495 · cited 1×
“International Guidelines consider FH patients at high cardiovascular risk and therefore the optimal LDL-c goal should be < 100 mg/dl [21,22] or to achieve at least a 50% reduction in LDL-c levels [18].”
BackgroundNeil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn422 · Cited by 425
Cited by
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Watts, G. F., Gidding, S., Wierzbicki, A. S., Toth, P. P., Alonso, R., Brown, W. V., Bruckert, E., Defesche, J., Lin, K. K., Livingston, M., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.025 · Cited by 377
Self-citationPérez de Isla, L., Alonso, R., Mata, N., Fernández-Pérez, C., Muñiz, O., Díaz-Díaz, J. L., Saltijeral, A., Fuentes-Jiménez, F., de Andrés, R., Zambón, D., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024541 · Cited by 342
Self-citationLipoprotein(a) Levels in Familial Hypercholesterolemia
Alonso, R., Andres, E., Mata, N., Fuentes-Jiménez, F., Badimón, L., López-Miranda, J., Padró, T., Muñiz, O., Díaz-Díaz, J. L., Mauri, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.063 · Cited by 323
Self-citation
Metadata
- Authors
- Mata, N., Alonso, R., Badimón, L., Padró, T., Fuentes, F., Muñiz, O., Perez-Jiménez, F., López-Miranda, J., Díaz, J. L., Vidal, J. I., Barba, A., Piedecausa, M., Sanchez, J. F., Irigoyen, L., Guallar, E., Ordovas, J. M., & Mata, P.
- Venue
- Lipids in Health and Disease
- Published
- 2011
- Volume
- 10
- Issue
- 1
- Pages
- 94
- ISSN
- 1476-511X (ISSN-L)
- OpenAlex
- W2105541785
- Cited by
- 136
- References
- 5
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). https://app.cochat.ai/papers/10.1186/1476-511x-10-94
- The paper
- Mata, N., Alonso, R., Badimón, L., Padró, T., Fuentes, F., Muñiz, O., Perez-Jiménez, F., López-Miranda, J., Díaz, J. L., Vidal, J. I., Barba, A., Piedecausa, M., Sanchez, J. F., Irigoyen, L., Guallar, E., Ordovas, J. M., & Mata, P. (2011). Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids in Health and Disease. https://doi.org/10.1186/1476-511x-10-94
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.